Clinically Relevant Biology of Hereditary Breast Cancer

Seminars in Oncology

Volumn 34, Issue 5, 2007, Pages 379-383

  Foulkes, William D ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PROTEIN CTIP; PROTEIN P53; PROTEIN ZBRK1; STAT1 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CYTOKINESIS; DNA REPAIR; FAMILIAL CANCER; GENE ISOLATION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; ONCOGENE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSCRIPTION REGULATION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION;

EID: 34848839832     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.07.010     Document Type: Article

References (51)

1. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 (1998) 1138-1145
2. Honrado E., Osorio A., Palacios J., et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25 (2006) 5837-5845
3. Agnarsson B.A., Jonasson J.G., Bjornsdottir I.B., et al. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 47 (1998) 121-127
4. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 (1997) 1505-1510
5. Bane A.L., Beck J.C., Bleiweiss I., et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31 (2007) 121-128
6. Jass J.R. Role of the pathologist in the diagnosis of hereditary non-polyposis colorectal cancer. Dis Markers 20 (2004) 215-224
7. Armes J.E., Egan A.J., Southey M.C., et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study. Cancer 83 (1998) 2335-2345
8. Thiffault I., Hamel N., Pal T., et al. Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer 90 (2004) 483-491
9. Johannsson O.T., Idvall I., Anderson C., et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33 3 (1997) 362-371
10. Karp S.E., Tonin P.N., Begin L.R., et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80 (1997) 435-441
11. Foulkes W.D., Metcalfe K., Sun P., et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10 (2004) 2029-2034
12. Lakhani S.R., van de Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (2002) 2310-2318
13. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 (2001) 539-548
14. Van't Veer L.J., Dai H.Y., and van de Vijver M.J. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
15. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
16. Scully R., Chen J., Plug A., et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88 (1997) 265-275
17. Sharan S.K., Morimatsu M., Albrecht U., et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386 (1997) 804-810
18. Mizuta R., Lasalle J.M., Cheng H.L., et al. RAB22 and RAB163/mouse BRCA2 - proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci U S A 94 (1997) 6927-6932
19. Wong A.K., Pero R., Ormonde P.A., et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272 (1997) 31941-31944
20. Moynahan M.E., Cui T.Y., and Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61 (2001) 4842-4850
21. Tassone P., Tagliaferri P., Perricelli A., et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88 (2003) 1285-1291
22. Yuan S.S.F., Lee S.Y., Chen G., et al. BRCA2 is required for ionizing radiation-induced assembly of rad51 complex in vivo. Cancer Res 59 (1999) 3547-3551
23. Patel K.J., Yu V.P., Lee H., et al. Involvement of Brca2 in DNA repair. Mol Cell 1 (1998) 347-357
24. Zhong Q., Chen C.F., Li S., et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285 (1999) 747-750
25. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
26. Hartman A.R., and Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 32 (2002) 180-184
27. Greenblatt M.S., Chappuis P.O., Bond J.P., et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res 61 (2001) 4092-4097
28. Kojic M., Yang H., Kostrub C.F., et al. The BRCA2-interacting protein DSS1 is vital for DNA repair, recombination, and genome stability in Ustilago maydis. Mol Cell 12 (2003) 1043-1049
29. Gudmundsdottir K., Lord C.J., Witt E., et al. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep 5 (2004) 989-993
30. Xia B., Sheng Q., Nakanishi K., et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22 (2006) 719-729
31. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297 (2002) 606-609
32. Offit K., Levran O., Mullaney B., et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95 (2003) 1548-1551
33. Reid S., Schindler D., Hanenberg H., et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39 (2007) 162-164
34. Xia B., Dorsman J.C., Ameziane N., et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39 (2007) 159-161
35. Rahman N., Seal S., Thompson D., et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39 (2007) 165-167
36. Tischkowitz M., Xia B., Sabbaghian N., et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 104 (2007) 6788-6793
37. Erkko H., Xia B., Nikkila J., et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446 (2007) 316-319
38. Mullan P.B., Quinn J.E., and Harkin D.P. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25 (2006) 5854-5863
39. Monteiro A.N., August A., and Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 93 (1996) 13595-13599
40. Abkevich V., Zharkikh A., Deffenbaugh A.M., et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41 (2004) 492-507
41. Phelan C.M., Dapic V., Tice B., et al. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42 (2005) 138-146
42. Hashizume R., Fukuda M., Maeda I., et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276 (2001) 14537-14540
43. Scully R., Anderson S.F., Chao D.M., et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A May 94 (1997) 5605-5610
44. Rummukainen J.K., Salminen T., Lundin J., et al. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 14 (2001) 1030-1035
45. Grushko T.A., Dignam J.J., Das S., et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10 (2004) 499-507
46. Tirkkonen M., Johannsson O., Agnarsson B.A., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57 (1997) 1222-1227
47. Mai S., and Garini Y. Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle 4 (2005) 1327-1331
48. Wang Q., Zhang H., Kajino K., et al. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17 (1998) 1939-1948
49. Foulkes W.D. BRCA1 functions as a breast stem cell regulator. J Med Genet 41 (2004) 1-5
50. Daniels M.J., Wang Y., Lee M., et al. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306 (2004) 876-879
51. Delaval B., Ferrand A., Conte N., et al. Aurora B -TACC1 protein complex in cytokinesis. Oncogene 23 (2004) 4516-4522